Sílvia Marcé
About
Sílvia Marcé is a scholar working on Genetics, Hematology and Pathology and Forensic Medicine.
According to data from OpenAlex, Sílvia Marcé has authored 20 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Genetics, 10 papers in Hematology and 8 papers in Pathology and Forensic Medicine. Recurrent topics in Sílvia Marcé's work include Chronic Lymphocytic Leukemia Research (11 papers), Lymphoma Diagnosis and Treatment (8 papers) and Chronic Myeloid Leukemia Treatments (8 papers). Sílvia Marcé is often cited by papers focused on Chronic Lymphocytic Leukemia Research (11 papers), Lymphoma Diagnosis and Treatment (8 papers) and Chronic Myeloid Leukemia Treatments (8 papers). Sílvia Marcé collaborates with scholars based in Spain and Germany. Sílvia Marcé's co-authors include Neus Villamor, Dolors Colomer, Elı́as Campo, Emili Montserrat, Beatríz Bellosillo, Armando López‐Guillermo, Francesc Bosch, Marı́a Rozman, Marta Crespo and Jordi Esteve and has published in prestigious journals such as New England Journal of Medicine, Blood and Oncogene.
In The Last Decade
Sílvia Marcé
19 papers receiving 1.5k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Sílvia Marcé Spain | 12 | 1.1k | 877 | 599 | 458 | 306 | 20 | 1.6k | ||
| Jerzy Z. Błoński Poland | 21 | 797 0.7× | 642 0.7× | 403 0.7× | 224 0.5× | 291 1.0× | 75 | 1.2k | ||
| Daniela Gottardi Italy | 11 | 605 0.5× | 379 0.4× | 405 0.7× | 353 0.8× | 193 0.6× | 19 | 1.0k | ||
| Pablo G. Longo Italy | 11 | 739 0.7× | 363 0.4× | 463 0.8× | 390 0.9× | 133 0.4× | 16 | 1.0k | ||
| Stacey M. Fernandes United States | 20 | 809 0.7× | 556 0.6× | 532 0.9× | 581 1.3× | 322 1.1× | 81 | 1.6k | ||
| Margaret S. Lucas United States | 15 | 1.2k 1.0× | 955 1.1× | 610 1.0× | 209 0.5× | 254 0.8× | 34 | 1.5k | ||
| Domenico Levato Italy | 20 | 674 0.6× | 461 0.5× | 387 0.6× | 309 0.7× | 168 0.5× | 29 | 974 | ||
| Francesca Arruga Italy | 20 | 550 0.5× | 213 0.2× | 332 0.6× | 502 1.1× | 312 1.0× | 60 | 1.3k | ||
| Herbert Eradat United States | 17 | 564 0.5× | 531 0.6× | 270 0.5× | 255 0.6× | 257 0.8× | 60 | 966 | ||
| Dariusz Wołowiec Poland | 20 | 370 0.3× | 323 0.4× | 621 1.0× | 401 0.9× | 661 2.2× | 81 | 1.4k | ||
| Joanna Góra‐Tybor Poland | 18 | 733 0.7× | 381 0.4× | 164 0.3× | 291 0.6× | 218 0.7× | 82 | 1.2k |
Countries citing papers authored by Sílvia Marcé
Since
Specialization
Citations
This map shows the geographic impact of Sílvia Marcé's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sílvia Marcé with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sílvia Marcé more than expected).
Fields of papers citing papers by Sílvia Marcé
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Sílvia Marcé. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sílvia Marcé. The network helps show where Sílvia Marcé may publish in the future.
Co-authorship network of co-authors of Sílvia Marcé
This figure shows the co-authorship network connecting the top 25 collaborators of Sílvia Marcé. A scholar is included among the top collaborators of Sílvia Marcé based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sílvia Marcé. Sílvia Marcé is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Marcé, Sílvia, Gustavo Tapia, Jordi Juncà, et al.. (2022). Flow cytometry to detect bone marrow involvement by follicular lymphoma. Cytometry Part B Clinical Cytometry. 102(6). 427–439.
2.
Estrada, Natàlia, Blanca Xicoy, Sílvia Marcé, et al.. (2022). P690: GENE MUTATIONAL PROFILE ASSOCIATED WITH TREATMENT FAILURE OR PROGRESSION IN CHRONIC MYELOID LEUKEMIA. HemaSphere. 6. 585–586.
3.
Marcé, Sílvia, Blanca Xicoy, Olga García, et al.. (2021). Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib. Journal of Clinical Medicine. 10(14). 3146–3146.
4.
Estrada, Natàlia, Blanca Xicoy, Fabian Beier, et al.. (2021). Influence of Telomere Length on the Achievement of Deep Molecular Response With Imatinib in Chronic Myeloid Leukemia Patients. Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona).
5.
Acha, Pamela, Laura Palomo, Francisco Fuster‐Tormo, et al.. (2021). Analysis of Intratumoral Heterogeneity in Myelodysplastic Syndromes with Isolated del(5q) Using a Single Cell Approach. Cancers. 13(4). 841–841.
6.
Malinverni, Roberto, Joan Bargay, Blanca Xicoy, et al.. (2021). Different methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survival. Clinical Epigenetics. 13(1). 9–9.
7.
Bargay, Joan, Blanca Xicoy, Olga García, et al.. (2018). Impact of mutational studies on the diagnosis and the outcome of high-risk myelodysplastic syndromes and secondary acute myeloid leukemia patients treated with 5-azacytidine. Oncotarget. 9(27). 19342–19355.
8.
Marcé, Sílvia, Montserrat Cortés, Lurdes Zamora, et al.. (2015). A thirty-five nucleotides BCR-ABL1 insertion mutation of controversial significance confers resistance to imatinib in a patient with chronic myeloid leukemia (CML). Experimental and Molecular Pathology. 99(1). 16–18.
9.
Sorigué, Marc, Josep‐María Ribera, Olga García, et al.. (2015). Highly variable mutational profile of ASXL 1 in myelofibrosis. European Journal Of Haematology. 97(4). 331–335.
10.
Marcé, Sílvia, Lurdes Zamora, Blanca Xicoy, et al.. (2013). Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors. Medicina Clínica. 141(3). 95–99.
11.
Ribera, Jordi, et al.. (2013). Usefullness of IGH/TCR PCR studies in lymphoproliferative disorders with inconclusive clonality by flow cytometry. Cytometry Part B Clinical Cytometry. n/a–n/a.
12.
Zamora, Lurdes, et al.. (2013). Usefulness of IGH/TCR PCR studies in lymphoproliferative disorders with inconclusive clonality by flow cytometry. Cytometry Part B Clinical Cytometry. 86(1). 25–31.
13.
Marcé, Sílvia, Olga Balagué, Luís Colomo, et al.. (2006). Lack of Methylthioadenosine Phosphorylase Expression in Mantle Cell Lymphoma Is Associated with Shorter Survival: Implications for a Potential Targeted Therapy. Clinical Cancer Research. 12(12). 3754–3761.
14.
Marcé, Sílvia, Míriam Molina‐Arcas, Neus Villamor, et al.. (2006). Expression of human equilibrative nucleoside transporter 1 (hENT1) and its correlation with gemcitabine uptake and cytotoxicity in mantle cell lymphoma.. PubMed. 91(7). 895–902.
15.
Ferrer, Ana, Sílvia Marcé, Beatríz Bellosillo, et al.. (2004). Activation of mitochondrial apoptotic pathway in mantle cell lymphoma: high sensitivity to mitoxantrone in cases with functional DNA-damage response genes. Oncogene. 23(55). 8941–8949.
16.
Martı́nez, Antonio, Beatríz Bellosillo, Francesc Bosch, et al.. (2004). Nuclear Survivin Expression in Mantle Cell Lymphoma Is Associated with Cell Proliferation and Survival. American Journal Of Pathology. 164(2). 501–510.
17.
Molina‐Arcas, Míriam, Sílvia Marcé, Neus Villamor, et al.. (2004). Equilibrative nucleoside transporter-2 (hENT2) protein expression correlates with ex vivo sensitivity to fludarabine in chronic lymphocytic leukemia (CLL) cells. Leukemia. 19(1). 64–68.
18.
Crespo, Marta, Francesc Bosch, Neus Villamor, et al.. (2003). ZAP-70 Expression as a Surrogate for Immunoglobulin-Variable-Region Mutations in Chronic Lymphocytic Leukemia. New England Journal of Medicine. 348(18). 1764–1775.
19.
Bellosillo, Beatríz, Neus Villamor, Armando López‐Guillermo, et al.. (2002). Spontaneous and drug-induced apoptosis is mediated by conformational changes of Bax and Bak in B-cell chronic lymphocytic leukemia. Blood. 100(5). 1810–1816.
20.
Bellosillo, Beatríz, Neus Villamor, Armando López‐Guillermo, et al.. (2001). Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species. Blood. 98(9). 2771–2777.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Jerzy Z. Błoński Breakdown of academic impact, for papers by Daniela Gottardi Breakdown of academic impact, for papers by Pablo G. Longo Breakdown of academic impact, for papers by Stacey M. Fernandes Breakdown of academic impact, for papers by Margaret S. Lucas Breakdown of academic impact, for papers by Domenico Levato Breakdown of academic impact, for papers by Francesca Arruga Breakdown of academic impact, for papers by Herbert Eradat Breakdown of academic impact, for papers by Dariusz Wołowiec Breakdown of academic impact, for papers by Joanna Góra‐Tybor